Építés alatt – nem éles oldal
Belépés
Résztvevőt keres1. fázis

Clinical Study of CD19 Targeted Universal Chimeric Antigen Receptor T Lymphocytes (UCAR-T) for the Treatment of Refractory Juvenile Dermatomyositis (RJDM)

A legfontosabb adatok

Ki végzi
Chongqing Precision Biotech Co., Ltd
Hol
Kína1 helyszín, 1 országbanVálassz országot a helyszínekhez
Azonosító
Állapot
Toboroz
Fázis
1. fázis
Résztvevők
18 fő, tervezett
Kezdés
2024. nov. 11.
Várható befejezés
2027. nov. 10.
A vizsgálat típusa
Beavatkozással járó
A vizsgált kezelések
  • Anti-CD19 UCAR-T cells
A regiszteradat frissítve
2024. november 13.

Ki vehet részt

MI-összefoglaló

A vizsgálat saját részvételi feltételeiből. Gép olvasta ki az oldalon álló regiszterszövegből, ezért tévedhet. Hogy ki vehet részt, azt a lenti regiszterszöveg és a vizsgálat csapata dönti el.

The trial is looking for people aged 5 or older with juvenile dermatomyositis that has not responded to usual treatment. They will get universal CAR-T cells aimed at CD19.

Életkor
5 years and older
Nem
All sexes
A betegség stádiuma
Refractory juvenile dermatomyositis, meaning hard to treat. The disease must not have responded, or the person could not take the medicines. It must also show at least one of these: fast worsening or lung, heart or gut involvement, calcium deposits under the skin or in muscles and joints, rashes or ulcers that keep coming back, or ongoing muscle weakness. People with immune-mediated necrotizing myopathy and SRP or HMGCR antibodies can also join. Heart, kidney, liver and lung function must be mostly normal.
Korábbi kezelés
Must have had glucocorticoids (prednisone 1-2mg/kg/d or similar) for at least 6 months plus at least two immunosuppressants, without enough benefit or with side effects that could not be tolerated. Cannot have had CAR-T cell therapy before, unless the doctor judges the risk gone.
Biomarker vagy leletérték
For immune-mediated necrotizing myopathy: positive SRP or HMGCR antibodies.

A részvétel fő kizáró okai

  • Severe, active or uncontrolled infections, including tuberculosis, hepatitis B or C, HIV or syphilis
  • Active cancer or a past cancer, except removed basal cell skin cancer
  • Congenital heart disease, heart attack within 6 months or severe heart rhythm problems
  • Organ or stem cell transplant within 3 months before screening
  • Pregnancy, live vaccines within 4 weeks, or other trials within 3 months

A regiszter feltételei, szó szerint

Mind a 20 feltétel megnézéseKevesebb

Ki vehet részt

  • (1) Age ≥ 5 years old
  • (2) Diagnosis of juvenile dermatomyositis (JDM) according to Bohan and Peter criteria
  • (3) Meeting the classification criteria for RJDM, and meeting condition ① and any one of ② to ⑤ conditions:; Intolerance or inadequate response to glucocorticoids (prednisone 1-2mg/kg/d or equivalent dose of other hormones) and at least two immunosuppressants, with hormone therapy lasting for at least 6 months; Rapid progression of the disease and/or involvement of organs such as lungs, heart, and gastrointestinal tract; Calcification of subcutaneous or muscular and articular tissues; Repeated skin rashes or ulcers; Repeated or persistent muscle weakness (muscle magnetic resonance imaging indicating widespread, diffuse edema or a Children's Myositis Assessment Scale (CMAS) score < 48, and at least two abnormal results among the following five core measurement indicators: Physician's Global Assessment (PhGA) ≥ 2cm, Patient's Global Assessment (PtGA) ≥ 2cm, Disease Activity Score (DAS) ≥ 2 points, Child Health Assessment Questionnaire (C-HAQ) total score ≥ 0.25 points, and muscle enzyme level > 1.5 times the upper limit of normal (ULN))
  • (4)Patients with immune-mediated necrotizing myopathy who are positive for SRP or HMGCR antibodies meet the criteria for RJDM and can be directly included
  • (5) Basic normal function of important organs:; Cardiac function: Left ventricular ejection fraction (LVEF) ≥55%, with no significant abnormalities observed in the electrocardiogram; Renal function: eGFR ≥ 30mL/min/1.73m2; Liver function: AST and ALT ≤3.0 ULN, total bilirubin ≤2.0×ULN (excluding those caused by primary diseases); Pulmonary function: SpO2 ≥92%
  • (6) Female subjects of childbearing age have a negative result in the urine pregnancy test and agree to take effective contraceptive measures during the trial until one year after infusion
  • (7) The patient or their guardian agrees to participate in this clinical trial and signs an informed consent form, indicating their understanding of the purpose and procedures of the clinical trial and their willingness to participate in the study

Ki nem vehet részt

  • (1) Previously received CAR-T cell therapy (except for those whose safety risks have been judged as eliminated by the investigator)
  • (7) Received solid organ transplantation or hematopoietic stem cell transplantation within 3 months before screening; or presence of acute graft-versus-host disease (GVHD) of grade 2 or above within 2 weeks before screening
  • (9) Received live vaccines within 4 weeks before screening
  • (11) Participated in other clinical trials within 3 months before enrollment
  • (2) Accompanied by primary immunodeficiency disease or severe secondary immunodeficiency disease that has not been corrected
  • (3) Accompanied by severe, active, or uncontrolled infectious diseases, including but not limited to active tuberculosis, latent tuberculous infection, active viral hepatitis, etc
  • (4) Known to have active malignant diseases or confirmed malignancies before screening (including hematological malignancies and solid tumors, except for resected and cured cutaneous basal cell carcinoma)
  • (5) Suffering from congenital heart disease or having a history of acute myocardial infarction within 6 months, or severe arrhythmia (including multifocal frequent ventricular supraventricular tachycardia, ventricular tachycardia, etc.); or complicated with moderate to large pericardial effusion, severe myocarditis, etc.; or unstable vital signs requiring vasopressors to maintain blood pressure
  • (6) Accompanied by other diseases that require long-term use of glucocorticoids or immunosuppressants
  • (8) Positive for hepatitis B surface antigen (HBsAg) or hepatitis B core antibody (HBcAb) and peripheral blood hepatitis B virus (HBV) DNA titer detection is greater than the normal reference range; or positive for hepatitis C virus (HCV) antibody and peripheral blood hepatitis C virus (HCV) RNA titer detection is greater than the normal reference range; or positive for human immunodeficiency virus (HIV) antibody; or positive for syphilis test
  • (12) Other conditions that the investigator considers unsuitable for participation in the study
  • Subjects meeting any of the following criteria will be excluded from this trial:
  • (10) Positive blood pregnancy test

Ennek a vizsgálatnak nincs helyszíne itt: Egyesült Államok.

Egy országban van helyszíne. Válassz országot, hogy lásd a helyszíneket.

A vizsgálatról

Mit akar kideríteni a vizsgálat

This study is an open-label, single-arm, dose-escalation trial primarily designed to evaluate the safety and efficacy of a universal CAR-T cell therapy targeting CD19 in the treatment of patients with RJDM. Additionally, the study aims to characterize its pharmacokinetic and pharmacodynamic properties, explore its role in immune system reconstitution, and assess long-term survival benefits.

A vizsgálat csoportja

  • Anti-CD19 UCAR-T cellsA vizsgált kezelés

Kérdések a vizsgálat csapatának

  1. Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
  2. Megtérítik az utazási költséget?
  3. Megtarthatom a saját orvosomat?
  4. Mi történik, ha ki akarok lépni?

Contact the study team: see the registry record → Contacts and Locations

Oldal nyomtatása az orvosomnak

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
MI-összefoglaló
A vizsgálat saját részvételi feltételeiből. Gépi kiolvasás: 2026. november 14.
A regiszteradat frissítve
2024. november 13.